DK0565634T3 - Angiotensin-II-receptorblokkersammensætninger - Google Patents
Angiotensin-II-receptorblokkersammensætningerInfo
- Publication number
- DK0565634T3 DK0565634T3 DK92904382T DK92904382T DK0565634T3 DK 0565634 T3 DK0565634 T3 DK 0565634T3 DK 92904382 T DK92904382 T DK 92904382T DK 92904382 T DK92904382 T DK 92904382T DK 0565634 T3 DK0565634 T3 DK 0565634T3
- Authority
- DK
- Denmark
- Prior art keywords
- angiotensin
- receptorblokkersammensætninger
- blocker
- diuretic
- beta
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
- A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
- A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
- A01N43/64—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with three nitrogen atoms as the only ring hetero atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/415—1,2-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/553—Renin inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/55—Protease inhibitors
- A61K38/556—Angiotensin converting enzyme inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Hematology (AREA)
- Immunology (AREA)
- Gastroenterology & Hepatology (AREA)
- Biomedical Technology (AREA)
- Agronomy & Crop Science (AREA)
- Vascular Medicine (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Urology & Nephrology (AREA)
- Obesity (AREA)
- Pest Control & Pesticides (AREA)
- Plant Pathology (AREA)
- Dentistry (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Environmental Sciences (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US62880790A | 1990-12-14 | 1990-12-14 | |
PCT/US1991/009362 WO1992010097A1 (en) | 1990-12-14 | 1991-12-13 | Angiotensin ii receptor blocking compositions |
Publications (1)
Publication Number | Publication Date |
---|---|
DK0565634T3 true DK0565634T3 (da) | 1999-09-27 |
Family
ID=24520386
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DK92904382T DK0565634T3 (da) | 1990-12-14 | 1991-12-13 | Angiotensin-II-receptorblokkersammensætninger |
Country Status (14)
Country | Link |
---|---|
EP (1) | EP0565634B1 (da) |
JP (1) | JP3398379B2 (da) |
KR (1) | KR100222252B1 (da) |
AT (1) | ATE177634T1 (da) |
AU (1) | AU656551B2 (da) |
CA (1) | CA2098176C (da) |
DE (2) | DE69131021T2 (da) |
DK (1) | DK0565634T3 (da) |
ES (1) | ES2130170T3 (da) |
GR (1) | GR3030293T3 (da) |
HK (1) | HK1012209A1 (da) |
LU (1) | LU91234I2 (da) |
NL (1) | NL300115I2 (da) |
WO (1) | WO1992010097A1 (da) |
Families Citing this family (44)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5185351A (en) * | 1989-06-14 | 1993-02-09 | Smithkline Beecham Corporation | Imidazolyl-alkenoic acids useful as angiotensin II receptor antagonists |
NZ242724A (en) * | 1991-05-15 | 1994-09-27 | Du Pont | Synergistic composition comprising an angiotensin-ii receptor antagonist and a calcium channel blocker |
GB9117361D0 (en) * | 1991-08-12 | 1991-09-25 | Euro Celtique Sa | Oral dosage form |
JP3057471B2 (ja) | 1993-06-07 | 2000-06-26 | 武田薬品工業株式会社 | アンジオテンシンii介在性諸疾患の予防または治療剤 |
CA2125251C (en) * | 1993-06-07 | 2005-04-26 | Yoshiyuki Inada | A pharmaceutical composition for angiotensin ii-mediated diseases |
US5721263A (en) | 1993-06-07 | 1998-02-24 | Takeda Chemical Industries, Ltd. | Pharmaceutical composition for angiotensin II-mediated diseases |
EP0629408A1 (en) * | 1993-06-16 | 1994-12-21 | LABORATOIRES MERCK, SHARP & DOHME-CHIBRET | Combination of angiotensin converting enzyme inhibitors and AII antagonists |
CA2168066A1 (en) * | 1995-02-08 | 1996-08-09 | James R. Powell | Treatment of hypertension and congestive heart failure |
WO1997002032A1 (en) * | 1995-06-30 | 1997-01-23 | Merck & Co., Inc. | Method of treating renal disease using an ace inhibitor and an aii antagonist |
RU2188013C2 (ru) * | 1996-04-05 | 2002-08-27 | Такеда Кемикал Индастриз, Лтд. | Комбинация, содержащая соединение, имеющее ангиотензин ii антагонистическую активность |
WO1997049392A1 (en) * | 1996-06-24 | 1997-12-31 | Merck & Co., Inc. | A composition of enalapril and losartan |
US6087386A (en) * | 1996-06-24 | 2000-07-11 | Merck & Co., Inc. | Composition of enalapril and losartan |
KR100508044B1 (ko) * | 1997-08-06 | 2005-08-17 | 스미스클라인 비참 코포레이션 | 에프로사르탄 아르기닌 전하-중화-복합체와 그의 제조 및제형화 방법 |
US6204281B1 (en) | 1998-07-10 | 2001-03-20 | Novartis Ag | Method of treatment and pharmaceutical composition |
IL140905A0 (en) * | 1998-07-20 | 2002-02-10 | Smithkline Beecham Corp | Bioenhanced formulations comprising eprosartan in oral solid dosage form |
CN101011390A (zh) | 1999-01-26 | 2007-08-08 | 诺瓦提斯公司 | 血管紧张素ⅱ受体拮抗剂在治疗急性心肌梗塞中的应用 |
US6395728B2 (en) | 1999-07-08 | 2002-05-28 | Novartis Ag | Method of treatment and pharmaceutical composition |
US6448281B1 (en) | 2000-07-06 | 2002-09-10 | Boehringer Ingelheim (Canada) Ltd. | Viral polymerase inhibitors |
US8168616B1 (en) | 2000-11-17 | 2012-05-01 | Novartis Ag | Combination comprising a renin inhibitor and an angiotensin receptor inhibitor for hypertension |
PT1507558E (pt) * | 2002-05-17 | 2011-11-23 | Novartis Ag | Composição farmacêutica compreendendo um inibidor de renina, um bloqueador do canal de cálcio e um diurético |
PE20040468A1 (es) * | 2002-05-17 | 2004-09-14 | Novartis Ag | Combinacion de compuestos organicos |
EG24716A (en) * | 2002-05-17 | 2010-06-07 | Novartis Ag | Combination of organic compounds |
EP1531879A1 (en) * | 2002-06-28 | 2005-05-25 | Novartis AG | Use of organic compounds |
RS20050590A (en) | 2003-01-31 | 2007-09-21 | Sankyo Company Limited, | Medicine for prevention of and treatment for arteriosclerosis and hypertension |
CN103304541A (zh) | 2004-02-20 | 2013-09-18 | 贝林格尔.英格海姆国际有限公司 | 病毒聚合酶抑制剂 |
JP2007527915A (ja) * | 2004-03-08 | 2007-10-04 | ワイス | イオンチャンネルモジュレーター |
CA2558020A1 (en) * | 2004-03-17 | 2005-09-29 | Novartis Ag | Use of renin inhibitors in therapy |
EP1750862B1 (en) | 2004-06-04 | 2011-01-05 | Teva Pharmaceutical Industries Ltd. | Pharmaceutical composition containing irbesartan |
US7531560B2 (en) | 2004-11-10 | 2009-05-12 | Boehringer Ingelheim Pharmaceuticals, Inc. | Anti-cytokine heterocyclic compounds |
DE102005031577A1 (de) * | 2005-07-06 | 2007-01-11 | Bayer Healthcare Ag | Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten |
WO2007056324A2 (en) * | 2005-11-08 | 2007-05-18 | Novartis Ag | Combination of an angiotensin ii receptor blocker, a calcium channel blocker and another active agent |
US20100143470A1 (en) * | 2006-10-30 | 2010-06-10 | Hanall Pharmaceutical Company, Ltd | Controlled release pharmaceutical composition containing thiazides and angiotensin-ii-receptor blockers |
ES2393885T7 (es) | 2007-06-04 | 2014-01-30 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros trastornos |
US8969514B2 (en) | 2007-06-04 | 2015-03-03 | Synergy Pharmaceuticals, Inc. | Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases |
EP2275093A2 (en) | 2008-04-10 | 2011-01-19 | HanAll Biopharma Co., Ltd. | Pharmaceutical formulation |
WO2009149279A2 (en) | 2008-06-04 | 2009-12-10 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders |
ES2624828T3 (es) | 2008-07-16 | 2017-07-17 | Synergy Pharmaceuticals Inc. | Agonistas de la guanilato ciclasa útiles para el tratamiento de trastornos gastrointestinales, inflamación, cáncer y otros |
AR073380A1 (es) | 2008-09-25 | 2010-11-03 | Takeda Pharmaceutical | Composicion farmaceutica solida. comprimido multicapa |
DE102008059206A1 (de) * | 2008-11-27 | 2010-06-10 | Bayer Schering Pharma Aktiengesellschaft | Pharmazeutische Darreichungsform enthaltend Nifedipin oder Nisoldipin und einen Angiotensin-II Antagonisten und/oder ein Diuretikum |
US9616097B2 (en) | 2010-09-15 | 2017-04-11 | Synergy Pharmaceuticals, Inc. | Formulations of guanylate cyclase C agonists and methods of use |
CA2872542A1 (en) | 2012-05-07 | 2013-11-14 | Bayer Pharma Aktiengesellschaft | Process for manufacturing a pharmaceutical dosage form comprising nifedipine and candesartan cilexetil |
WO2014151200A2 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Compositions useful for the treatment of gastrointestinal disorders |
WO2014151206A1 (en) | 2013-03-15 | 2014-09-25 | Synergy Pharmaceuticals Inc. | Agonists of guanylate cyclase and their uses |
RS65632B1 (sr) | 2013-06-05 | 2024-07-31 | Bausch Health Ireland Ltd | Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA1338238C (en) * | 1988-01-07 | 1996-04-09 | David John Carini | Angiotensin ii receptor blocking imidazoles and combinations thereof with diuretics and nsaids |
DK0403159T3 (da) * | 1989-06-14 | 2000-08-14 | Smithkline Beecham Corp | Imidazolylalkensyrer |
IE910913A1 (en) * | 1990-03-20 | 1991-09-25 | Sanofi Sa | N-substituted heterocyclic derivates, their preparation¹and pharmaceutical compositions containing them |
FR2681067B1 (fr) * | 1991-09-10 | 1993-12-17 | Elf Sanofi | Derives heterocycliques n-substitues, leur preparation, les compositions pharmaceutiques en contenant. |
-
1991
- 1991-12-13 JP JP50431592A patent/JP3398379B2/ja not_active Expired - Lifetime
- 1991-12-13 AU AU91782/91A patent/AU656551B2/en not_active Expired
- 1991-12-13 WO PCT/US1991/009362 patent/WO1992010097A1/en active IP Right Grant
- 1991-12-13 DE DE69131021T patent/DE69131021T2/de not_active Expired - Lifetime
- 1991-12-13 AT AT92904382T patent/ATE177634T1/de active
- 1991-12-13 DE DE1991631021 patent/DE10399008I1/de active Pending
- 1991-12-13 DK DK92904382T patent/DK0565634T3/da active
- 1991-12-13 ES ES92904382T patent/ES2130170T3/es not_active Expired - Lifetime
- 1991-12-13 KR KR1019930701810A patent/KR100222252B1/ko not_active IP Right Cessation
- 1991-12-13 EP EP92904382A patent/EP0565634B1/en not_active Expired - Lifetime
- 1991-12-13 CA CA002098176A patent/CA2098176C/en not_active Expired - Lifetime
-
1998
- 1998-12-15 HK HK98113489A patent/HK1012209A1/xx not_active IP Right Cessation
-
1999
- 1999-05-20 GR GR990401379T patent/GR3030293T3/el unknown
-
2003
- 2003-02-21 NL NL300115C patent/NL300115I2/nl unknown
-
2006
- 2006-04-12 LU LU91234C patent/LU91234I2/fr unknown
Also Published As
Publication number | Publication date |
---|---|
AU9178291A (en) | 1992-07-08 |
CA2098176C (en) | 2006-12-12 |
ES2130170T3 (es) | 1999-07-01 |
JPH06503834A (ja) | 1994-04-28 |
DE69131021T2 (de) | 1999-08-12 |
DE69131021D1 (de) | 1999-04-22 |
HK1012209A1 (en) | 1999-07-30 |
NL300115I1 (nl) | 2003-05-01 |
NL300115I2 (nl) | 2003-09-01 |
EP0565634A4 (en) | 1996-04-17 |
CA2098176A1 (en) | 1992-06-14 |
WO1992010097A1 (en) | 1992-06-25 |
DE10399008I1 (de) | 2006-06-08 |
EP0565634A1 (en) | 1993-10-20 |
ATE177634T1 (de) | 1999-04-15 |
JP3398379B2 (ja) | 2003-04-21 |
AU656551B2 (en) | 1995-02-09 |
GR3030293T3 (en) | 1999-09-30 |
KR930702895A (ko) | 1993-11-29 |
LU91234I2 (fr) | 2006-06-12 |
EP0565634B1 (en) | 1999-03-17 |
KR100222252B1 (ko) | 1999-10-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DK0565634T3 (da) | Angiotensin-II-receptorblokkersammensætninger | |
ES2149451T3 (es) | Antagonistas alfa-1-adrenergicos de hexahidrobenz(e)isoindol triciclico sustituido. | |
NO996352D0 (no) | <Kappa>-antagenist-forbindelser, farmasoeytiske sammensetninger og fremgangsmåte for forebygging og behandling av pruritus | |
ES2178157T3 (es) | Tratamiento de arritmias mediante la inhibicion de una proteina quinasa multifuncional dependiente de calcio/calmodulina. | |
BG102976A (en) | Method for the preparation of drospyrenon (6 beta,7 beta: 15 beta,16 beta - dimethylene-3-oxo-17 alpha -pregn-4-ene-21,17-carbolacton, drsp)as well as 7 alpha-(3-hydroxy-1-propyl)-(6 beta,7 beta: 15 beta,16 beta -dirmethylene-5 beta-androstan-3 beta,5,17 beta -triol (zk 92836) and (6 beta,7 beta: 15 beta,16 beta - dimethylene-5 beta-hydroxy-3-oxo-17 alpha -androstan-21, 17-carbolacton (90965) as intermediate compounds of the method | |
DK0805812T3 (da) | Bicyklisk substitueret hexahydrobenz[e]isoindol som alfa-1-adrenerge antagonister | |
IL70882A0 (en) | Certain benzazocinone and benzazoninone derivatives | |
NZ333723A (en) | A synergistic combination of an insulin resistance improving agent and an angiotensin II receptor antagonist or an angiotensin converting enzyme inhibitor | |
MX9801890A (es) | Nuevos compuestos antagonistas selectivos del receptor nk3 humano, procedimiento para su obtencion y composiciones farmaceuticas que los contienen. | |
EP0726072A3 (en) | Composition for the treatment of hypertension and congestive heart failure, containing an angiotensin II antagonist and an endopeptidase inhibitor | |
AU8534291A (en) | Renal-selective angiotensin ii antagonists for treatment of hypertension | |
BR9809848A (pt) | Composição | |
AU6187898A (en) | Method for preventing or treating low renin hypertension by administering an endothelin antagonist | |
ES2175437T3 (es) | Composicion de enalapril y losartan. | |
ATA156496A (de) | Pharmazeutische zusammensetzung | |
NO992661L (no) | Benzopyranopyrrol og benzopyranopyridin <alfa>-1 adrenerge forbindelser | |
MX9708557A (es) | Nuevo uso farmacologico de los antagonistas del receptor aii. | |
AR011730A1 (es) | UNA FORMA FARMACÉUTICA DE CANTIDADES FIJAS DE UN INIHIBIDOR DE LA ENZIMA CONVERSORA DE ANGIOTENSINA Y DE UN ANTAGONISTA DEL CANAL DE CALCIO , COMPOSICIoN FARMACÉUTICAMENTE ACEPTABLE QUE COMPRENDE DICHA FORMA FARMACÉUTICA , PROCEDIMIENTO PARA LA OBTENCIoN DE DICHA COMPOSICIoN FARMACÉUTICAMENTE ACEPTA | |
ATE282416T1 (de) | Die verwendung von nk-1 rezeptor antagonisten für die behandlung von substanz-verwendung störungen | |
AR005830A1 (es) | Metodo y aparato para mitigar interferencias causadas por un sistema de comunicacion sobrepuesta | |
EA199800533A1 (ru) | Композиция для лечения боли | |
ES2185042T3 (es) | Inhibidores de la trombina. | |
NO981188D0 (no) | 5-HT3-reseptorantagonister for dyskinesi | |
AR010987A1 (es) | Composicion farmaceutica y metodo para tratar un trastorno compulsivo. | |
KR970047895U (ko) | Cdma방식 이동전화 교환기의 이.엠.아이 차단장치 |